HBW
LGND icon

Hazlett, Burt & Watson’s Ligand Pharmaceuticals LGND Stock Holding History

Hazlett, Burt & Watson’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-112
Closed -$6K – 629
2022
Q3 		$6K Hold
112
– – 0.01% 500
2022
Q2 		$6K Hold
112
– – 0.01% 492
2022
Q1 		$8K Buy
+112
New +$8.13K 0.01% 487

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hazlett, Burt & Watson's LGND Position: Q4 2022 in Review

Hazlett, Burt & Watson sold out of Ligand Pharmaceuticals (LGND) in Q4 2022, closing a stake of 112 shares — an estimated $6K sold.

Hazlett, Burt & Watson first reported a position in LGND in Q1 2022 and held it in 3 quarters. The position peaked at $8K in Q1 2022. 198 funds tracked by Wall St. Rank hold LGND as of Q4 2022.

  • Hazlett, Burt & Watson reported no remaining Ligand Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Hazlett, Burt & Watson sold 112 Ligand Pharmaceuticals shares in Q4 2022, an estimated $6K.
  • Hazlett, Burt & Watson first reported a position in Ligand Pharmaceuticals in Q1 2022 and held it in 3 quarters.
  • Hazlett, Burt & Watson's Ligand Pharmaceuticals position peaked at $8K in Q1 2022.
  • 198 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2022.

Based on Hazlett, Burt & Watson's 13F filing for Q4 2022, filed 25 Jan 2023.